A kind of a kind of method for handling triple negative breast cancers in mammal comprises the steps of:: wherein R1 is the pharmaceutically acceptable dosage that there is the alkyl of a carbon number of 1-4 to facilitate a kind of compound of a patient, it is a kind of thienotriazolodiazepine compounds of formula (1), R2 is a hydrogen atom One halogen atom Or alkyl, there is a carbon number of the 1-4 optionally replaced by a halogen atom or monohydroxy, R3 is a halogen atom Alkyl, the alkoxy of a carbon number that phenyl is optionally replaced by a halogen atom, with 1-4, the carbon number with 1-4 or containing cyanogen - NR5-(CH2) m-R6 wherein R5 is a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and R6 is phenyl or pyridyl optionally substituted by a halogen atom or - NR7 - CO - ( CH2 ) nR8 wherein R7 is a hydrogen atom or alkyl having a carbon number of 1 - 4 , n is an integer of 0 - 2 , and R8 is phenyl or pyridyl optionally substituted by a halogen atom , and R4 is - ( CH2 ) n - CO - NH - R9 wherein a is an integer of 1 - 4 , and R9 is alkyl having a carbon number of 1 - 4 The hydroxyalkyl of a carbon number with 1-4 The alkoxy of a carbon number with 1-4 Or phenyl or the pyridyl group optionally replaced by the alkyl of a carbon number with 1-4, a carbon number, amino or a hydroxyl or-(CH2) b-alkoxy of COOR10 with 1-4, wherein b is an integer of 1-4, R10 is alkyl, it has a carbon number of its 1-4, or pharmaceutically acceptable salt or monohydrate or a solvent, in conjunction with one or more chemotherapeutic agents selected from the group being made of m-TOR inhibitor and mitotic inhibitor.
